VANCOUVER, ON --
November 20, 2019 -- InvestorsHub
NewsWire -- Nextleaf Solutions Ltd.
("Nextleaf", "OILS", or the
"Company") (CSE: OILS) (OTCQB: OILFF)
(FSE: L0MA), a company developing disruptive
intellectual property for extraction and purification of
cannabinoids, announced today the United States Patent and
Trademark Office has granted the Company its sixth U.S. patent
pertaining to a proprietary chilled cannabinoid extraction process
with downstream media treatment and filtration.
Nextleaf is pleased to
further announce it has been issued a patent by the Superintendency
of Industry and Commerce – the Colombian Government agency
that administers intellectual property rights – pertaining to the
Company's industrial-scale process of extraction, refinement, and
distillation of cannabinoids.
"Nextleaf being awarded 10
patents by four international patent offices in the key markets
of Canada, Australia, Colombia, and the United
States validates our technology and further reinforces our
vision of developing defendable intellectual property ("IP")
that improves CBD and THC oil economics globally," said Paul
Pedersen, CEO of Nextleaf.
The Company's patented
technology allows for lower-quality dried cannabis and hemp biomass
to be efficiently processed at scale into a high-purity THC and CBD
distilled oil, the key ingredient used in the manufacturing of
standardized cannabis 2.0 products. OILS believes that as cannabis
becomes commoditized, proprietary technology which allows companies
to establish a low-cost competitive advantage will become a focal
point of differentiation and a key driver of long-term
value.
"As more governments around
the world move to legalize cannabis, we expect to see large
multi-national companies, including tobacco and pharmaceutical
companies, acquire IP in order to protect their rights as part of
their broader strategy to dominate the global market for legal
cannabinoid-based products," stated Pedersen. "Recent acquisitions
by large players in the sector are evidence of the potential for
significant shareholder value creation through the formalization
and protection of IP."
Commercialization of
Intellectual Property
The Company is focused
commercializing its IP portfolio through toll processing, wholesale
of CBD and THC distillate, and licensing IP to partners operating
in other legal markets. Management feels there is significant value
in the Company's IP and has had advanced discussions with a number
of strategic parties regarding IP licensing. Management believes
over the next 12 months, Nextleaf can generate upwards of
$5MM-$10MM in gross revenue from IP licensing
alone. i
About Nextleaf
Solutions
Nextleaf Solutions Ltd.
("OILS") is developing
disruptive intellectual property for industrial-scale extraction,
purification, and formulation of cannabinoids. OILS owns a
portfolio of 10 issued patents and over 40 pending patents
pertaining to the production of high-purity, cannabinoid-rich
distillate, the key ingredient used in the manufacturing of
standardized CBD and THC infused products. OILS commercializes its
IP portfolio through IP licensing, B2B processing services, and
supplying THC and CBD oils to qualified Canadian and international
partners through Nextleaf Labs Ltd., a Health Canada licensed
Standard Processor.
Nextleaf Solutions trades
as OILS on the Canadian Securities
Exchange, OILFF on the OTCQB Market
in the United States,
and L0MA on the Frankfurt Stock
Exchange.
Follow OILS across social
media platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com
For further information,
please contact:
604-283-2301 (ext. 201)
investors@nextleafsolutions.com
On behalf of the Board
of Directors of the Company,
Paul Pedersen, CEO
CAUTIONARY
STATEMENT
Certain statements
contained in this press release constitute "forward-looking
statements". All statements other than statements of historical
fact contained in this press release, including, without
limitation, those regarding the Company's ability to capitalize on
its IP portfolio, expectations regarding lower concentrate costs
resulting from utilization of the Company's technology, changes in
the global market for cannabinoid-based products, the potential for
shareholder value creation through the formalization and protection
of IP, expected IP licensing revenues, levels of purity resulting
from the Company's patented technology, and the Company's
strategy, plans, objectives, goals and targets, and any statements
preceded by, followed by or that include the words "believe",
"expect", "aim", "intend", "plan", "continue", "will", "may",
"would", "anticipate", "estimate", "forecast", "predict",
"project", "seek", "should" or similar expressions or the negative
thereof, are forward-looking statements. These statements are not
historical facts but instead represent only the Company's
expectations, estimates and projections regarding future events.
These statements are not guarantees of future performance and
involve assumptions, risks and uncertainties that are difficult to
predict. Therefore, actual results may differ materially from what
is expressed, implied or forecasted in such forward-looking
statements. Additional factors that could cause actual results,
performance or achievements to differ materially include, but are
not limited to the risk factors discussed in the Company's MD&A
for the most recent fiscal period. Management provides
forward-looking statements because it believes they provide useful
information to investors when considering their investment
objectives and cautions investors not to place undue reliance on
forward-looking information. Consequently, all of the
forward-looking statements made in this press release are qualified
by these cautionary statements and other cautionary statements or
factors contained herein, and there can be no assurance that the
actual results or developments will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, the Company. These forward-looking
statements are made as of the date of this press release and the
Company assumes no obligation to update or revise them to reflect
subsequent information, events or circumstances or otherwise,
except as required by law. The CSE has not reviewed, approved
or disapproved the contents of this press
release.
